WALDENSTRÖM MACROGLOBULINEMIA (WM)
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA (WM) explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA (WM) trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to deeply shrink rare blood cancer
Disease control Not yet recruitingThis study tests a combination of targeted therapy (zanubrutinib) with a reduced-dose chemotherapy and an antibody drug for people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. About 43 participants will receive four cycles of the combo, then eight mont…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo aims to shorten treatment for rare blood cancer
Disease control Not yet recruitingThis early-phase trial tests a three-drug combination (ibrutinib, bendamustine, and rituximab) given for a fixed duration in people with Waldenström macroglobulinemia, a rare blood cancer. The study has two parts: first, finding the safest dose of bendamustine, and then testing t…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 26, 2026 15:28 UTC